Literature DB >> 12121900

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Eric Viaene1, Hugues Chanteux, Hélène Servais, Marie-Paule Mingeot-Leclercq, Paul M Tulkens.   

Abstract

The stability of antipseudomonal beta-lactams in concentrated solutions was examined in view of their potential administration by continuous infusion with external pumps (for intensive care patients) or with portable pumps carried under clothing (for cystic fibrosis patients). Aztreonam (100 g/liter), piperacillin (128 g/liter, with tazobactam), and azlocillin (128 g/liter) remained 90% stable for up to more than 24 h at 37 degrees C (mezlocillin [128 g/liter] was stable at 25 degrees C but not at 37 degrees C). Ceftazidime (120 g/liter), cefpirome (32 g/liter), and cefepime (50 g/liter) remained 90% stable for up to 24, 23.7, and 20.5 h at 25 degrees C but only for 8, 7.25, and 13 h at 37 degrees C, respectively. The control of temperature therefore appears to be critical for all three cephalosporins that cannot be recommended for use in portable pumps carried under clothes for prolonged periods for reasons of stability. Cefpirome and cefepime solutions developed an important color change (from light yellow to dark red) upon exposure when stored at 30 degrees C or higher. Degradation of ceftazidime was accompanied by the liberation of pyridine which, at 37 degrees C, was in excess of what is allowed by the U.S. Pharmacopeia, i.e., 1.1 mg/liter, after 8 and 12 h for drug concentrations of 12 and 8.3%, respectively. Imipenem and meropenem are too unstable (10% degradation at 25 degrees C after 3.5 and 5.15 h, respectively) to be recommended for use by continuous infusion. Faropenem, examined in comparison with imipenem and meropenem, proved as stable as aztreonam or piperacillin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121900      PMCID: PMC127357          DOI: 10.1128/AAC.46.8.2327-2332.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 2.  Serine beta-lactamases and penicillin-binding proteins.

Authors:  J M Ghuysen
Journal:  Annu Rev Microbiol       Date:  1991       Impact factor: 15.500

Review 3.  Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations.

Authors:  J W Mouton; A A Vinks
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

4.  High-performance liquid chromatographic assay for meropenem in serum.

Authors:  H Elkhaïli; S Niedergang; D Pompei; L Linger; D Leveque; F Jehl
Journal:  J Chromatogr B Biomed Appl       Date:  1996-11-08

5.  Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients.

Authors:  L Garcia-Capdevila; C López-Calull; C Arroyo; M A Moral; M A Mangues; J Bonal
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-04-25

6.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  High-performance liquid chromatographic determination of tazobactam and piperacillin in human plasma and urine.

Authors:  V Augey; P Y Grosse; G Albert; M Audran; F Bressolle
Journal:  J Chromatogr B Biomed Appl       Date:  1996-06-28

Review 8.  Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA.

Authors:  W A Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

9.  Influence of pH, temperature, and buffers on the kinetics of ceftazidime degradation in aqueous solutions.

Authors:  M Zhou; R E Notari
Journal:  J Pharm Sci       Date:  1995-05       Impact factor: 3.534

Review 10.  Beta-lactam antibiotics: is continuous infusion the preferred method of administration?

Authors:  T G Vondracek
Journal:  Ann Pharmacother       Date:  1995-04       Impact factor: 3.154

View more
  45 in total

1.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 3.  Systematic review of stability data pertaining to selected antibiotics used for extended infusions in outpatient parenteral antimicrobial therapy (OPAT) at standard room temperature and in warmer climates.

Authors:  Stephen John Perks; Cassie Lanskey; Niechole Robinson; Tilley Pain; Richard Franklin
Journal:  Eur J Hosp Pharm       Date:  2019-06-20

4.  Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.

Authors:  William A Prescott; Allison E Gentile; Jerod L Nagel; Rebecca S Pettit
Journal:  P T       Date:  2011-11

5.  How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?

Authors:  P Bourget; A Amin; C Dupont; M Abely; N Desmazes-Dufeu; J C Dubus; B-L Jouani; C Merlette; R Nové-Josserand; J Pages; R Panzo; F Vidal; F Voge; D Hubert
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Authors:  Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

8.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.

Authors:  Julia Langgartner; Antje Vasold; Thomas Glück; Michel Reng; Frieder Kees
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

Review 10.  Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Crit Care       Date:  2009-06-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.